ADRIBLASTINE Side Effects

7002198-8 | Febrile Bone Marrow Aplasia
on Sep 08, 2010 Male patient from FRANCE , 22 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Adriblastine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile bone marrow aplasia. Adriblastine dosage: 142.5 Mg, Single. During the same period patient was treated with METHOTREXATE (15 Mg, Single) (View Methotrexate Review and Methotrexate Label ), MABTHERA (712.5 Mg, Single) (View Mabthera Review and Mabthera Label ), ENDOXAN (2280 Mg, Single) (View Endoxan Review and Endoxan Label ), ELDISINE (3.8 Mg, Cyclic, On Day 1 And Day 5) (View Eldisine Review and Eldisine Label ), BLEOMYCIN (10 Mg, Cyclic, On Day 1 And Day 5) (View Bleomycin Review and Bleomycin Label ), SOLU MEDROL (120 Mg, 1x/day) (View Solu-medrol Review and Solu-medrol Label ), TRIFLUCAN (100 Mg, 1x/day) (View Triflucan Review and Triflucan Label ), VALACYCLOVIR HYDROCHLORIDE (1 G, 1x/day) (View Valacyclovir Hydrochloride Review and Valacyclovir Hydrochloride Label ). Patient was hospitalized.

7002187-3 | Febrile Bone Marrow Aplasia
Patient was taking Adriblastine (View Usage). Patient had the following side effects: febrile bone marrow aplasia on Sep 08, 2010 from FRANCE Additional patient health information: Male patient , 63 years of age, was diagnosed with type 2 diabetes mellitus and. Adriblastine dosage: 96 Mg, Single. During the same period patient was treated with MABTHERA (720 Mg, Single) (View Mabthera Review and Mabthera Label ), ENDOXAN (1440 Mg, Single) (View Endoxan Review and Endoxan Label ), VINCRISTINE (2 Mg, Single) (View Vincristine Review and Vincristine Label ), DIAMICRON (View Diamicron Review and Diamicron Label ), GLUCOPHAGE (Unk) (View Glucophage Review and Glucophage Label ), BISOPROLOL FUMARATE (2.5 Mg, 1x/day) (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), IRBESARTAN (300 Mg, 1x/day) (View Irbesartan Review and Irbesartan Label ), KARDEGIC (75 Unk, 1xday) (View Kardegic Review and Kardegic Label ). Patient was hospitalized.

6936355-3 | Agranulocytosis, Encephalopathy, Renal Tubular Disorder
Adverse event was reported on Aug 11, 2010 by a Male patient taking Adriblastine (View Usage) (Dosage: 30 Mg/m2, Cyclic) . Location: FRANCE , weighting 28.22 lb, After Adriblastine was administered, patient had the following side effects: agranulocytosis, encephalopathy, renal tubular disorder. During the same period patient was treated with HOLOXAN (1.6 G, Cyclic) (View Holoxan Review and Holoxan Label ), VINCRISTINE (1.5 Mg/m2, Cyclic) (View Vincristine Review and Vincristine Label ), ACTINOMYCIN D (1.5 Mg/m2, Cyclic) (View Actinomycin D Review and Actinomycin D Label ). Patient was hospitalized.

6927914-2 | Radiation Mucositis
on Aug 05, 2010 Female patient from FRANCE , 17 years of age, was diagnosed with burkitt's lymphoma and was treated with Adriblastine (View Usage). Patient experienced the following unwanted or unexpected effects: radiation mucositis. Adriblastine dosage: 60 Mg/m2, Single. During the same period patient was treated with VINCRISTINE (2 Mg, Single) (View Vincristine Review and Vincristine Label ), METHOTREXATE (3 G, Single) (View Methotrexate Review and Methotrexate Label ), ENDOXAN (250 Mg/m2, 2x/day) (View Endoxan Review and Endoxan Label ). Patient was hospitalized.


6925015-0 | Disorientation, Dysarthria, Memory Impairment, Nervous System Disorder, Tremor
on Aug 02, 2010 Male patient from FRANCE , 15 years of age, was treated with Adriblastine (View Usage). Patient had the following side effects: disorientation, dysarthria, memory impairment, nervous system disorder, tremor. Adriblastine dosage: 68 Mg, On Days 1 And 15. During the same period patient was treated with MABTHERA (650 Mg, Single) (View Mabthera Review and Mabthera Label ), ONCOVIN (1.75 Mg, Single) (View Oncovin Review and Oncovin Label ), CYCLOPHOSPHAMIDE (520 Mg, Single) (View Cyclophosphamide Review and Cyclophosphamide Label ), SOLUPRED (60 Mg, 2x/day) (View Solupred Review and Solupred Label ), VEPESID (210 Mg, From Da 1 To 5) (View Vepesid Review and Vepesid Label ), FASTURTEC (View Fasturtec Review and Fasturtec Label ).

6847930-9 | Pulmonary Fibrosis
Patient was taking Adriblastine (View Usage). After Adriblastine was administered, patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?) on Jul 08, 2010 from FRANCE Additional patient health information: Male patient , 56 years of age, . Adriblastine dosage: 50 Mg, Cyclic. During the same period patient was treated with BLEOMYCIN (20 Mg, Cyclic) (View Bleomycin Review and Bleomycin Label ), VELBE (10 Mg, Cyclic) (View Velbe Review and Velbe Label ), DETICENE (700 Mg, Cyclic) (View Deticene Review and Deticene Label ), DEXAMETHASONE MERCK (4 Mg, Cyclic) (View Dexamethasone Merck Review and Dexamethasone Merck Label ). Patient was hospitalized.

6822728-6 | Atrial Fibrillation, Cardiac Failure, Congestive Cardiomyopathy
Adverse event was reported on Jun 28, 2010 by a Male patient taking Adriblastine (View Usage) (Dosage: 50 Mg Daily Dose, Cyclic) was diagnosed with b-cell lymphoma and. Location: FRANCE , 67 years of age, Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), cardiac failure, congestive cardiomyopathy. During the same period patient was treated with MABTHERA (Cyclic) (View Mabthera Review and Mabthera Label ), ENDOXAN (750 Mg Daily Dose, Cyclic) (View Endoxan Review and Endoxan Label ), ONCOVIN (1.4 Mg Daily Dose, Cyclic) (View Oncovin Review and Oncovin Label ), PREDNISOLONE (40 Mg Daily Dose, Cyclic) (View Prednisolone Review and Prednisolone Label ), TRIATEC (5 Mg Daily Orally) (View Triatec Review and Triatec Label ), CARDENSIEL (2.5 Mg) (View Cardensiel Review and Cardensiel Label ), PREVISCAN (0.5 Dosage Form Daily) (View Previscan Review and Previscan Label ), OGASTRO (30 Mg Daily) (View Ogastro Review and Ogastro Label ). Patient was hospitalized.

6782149-1 | Pulmonary Fibrosis
on Jun 09, 2010 Male patient from FRANCE , 56 years of age, was treated with Adriblastine (View Usage). Patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?). Adriblastine dosage: 50 Mg, Cyclic. During the same period patient was treated with BLEOMYCIN (20 Mg, Cyclic) (View Bleomycin Review and Bleomycin Label ), VELBE (10 Mg, Cyclic) (View Velbe Review and Velbe Label ), DETICENE (700 Mg, Cyclic) (View Deticene Review and Deticene Label ), DEXAMETHASONE MERCK (4 Mg, Cyclic) (View Dexamethasone Merck Review and Dexamethasone Merck Label ). Patient was hospitalized.

6781494-3 | Acute Pulmonary Oedema, Atrial Fibrillation, Dyspnoea
on Jun 09, 2010 Female patient from FRANCE , 72 years of age, was treated with Adriblastine (View Usage). After Adriblastine was administered, patient had the following side effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), dyspnoea. Adriblastine dosage: 41.5 Mg, Single. During the same period patient was treated with SOLU MEDROL (66.4 Mg, Single) (View Solu-medrol Review and Solu-medrol Label ), ENDOXAN (664 Mg, Single) (View Endoxan Review and Endoxan Label ), ONCOVIN (1 Mg, Single) (View Oncovin Review and Oncovin Label ), OFLOCET (200 Mg, 2x/day) (View Oflocet Review and Oflocet Label ), MABTHERA (622.5 Mg, Single) (View Mabthera Review and Mabthera Label ), LOVENOX (0.5 Iu, 2x/day) (View Lovenox Review and Lovenox Label ), FORLAX (View Forlax Review and Forlax Label ), IMOVANE (As Needed) (View Imovane Review and Imovane Label ). Patient was hospitalized.

6729817-5 | Disorientation, Dysarthria, Memory Impairment, Nervous System Disorder, Tremor
Patient was taking Adriblastine (View Usage). Patient experienced the following unwanted or unexpected effects: disorientation, dysarthria, memory impairment, nervous system disorder, tremor on May 07, 2010 from FRANCE Additional patient health information: Male patient , 15 years of age, . Adriblastine dosage: 68 Mg, On Days 1 And 15. During the same period patient was treated with MABTHERA (650 Mg, Single) (View Mabthera Review and Mabthera Label ), ONCOVIN (1.75 Mg, Single) (View Oncovin Review and Oncovin Label ), ENDOXAN (520 Mg, Single) (View Endoxan Review and Endoxan Label ), SOLUPRED (60 Mg, 2x/day) (View Solupred Review and Solupred Label ), VEPESID (210 Mg, From Da 1 To 5) (View Vepesid Review and Vepesid Label ), FASTURTEC (View Fasturtec Review and Fasturtec Label ).

6676343-8 | Cytolytic Hepatitis
Adverse event was reported on Mar 31, 2010 by a Male patient taking Adriblastine (View Usage) (Dosage: 60 Mg/m2, Cyclic) was diagnosed with liposarcoma, jugular vein thrombosis and. Location: FRANCE , 39 years of age, Patient had the following side effects: cytolytic hepatitis. During the same period patient was treated with HOLOXAN (3000 Mg/m2, Cyclic) (View Holoxan Review and Holoxan Label ), UROMITEXAN (3000 Mg/m2, Cyclic) (View Uromitexan Review and Uromitexan Label ), BRISTOPEN (500 Mg, 6 Times Per Day) (View Bristopen Review and Bristopen Label ), INNOHEP (0.8 Ml Daily) (View Innohep Review and Innohep Label ), IXPRIM (View Ixprim Review and Ixprim Label ), GURONSAN (1 Df, 1x/day) (View Guronsan Review and Guronsan Label ), CELESTENE (4 Mg (2 Mg, 2x/day) From D1 To D3) (View Celestene Review and Celestene Label ), TARGOCID (Unk) (View Targocid Review and Targocid Label ). Patient was hospitalized.

6336674-8 | Pulmonary Fibrosis, Respiratory Distress
on Aug 20, 2009 Female patient from FRANCE , 32 years of age, was treated with Adriblastine (View Usage). After Adriblastine was administered, patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?), respiratory distress. Adriblastine dosage: 50 Mg, Every 2 Weeks. During the same period patient was treated with BLEOMYCIN SULFATE (20 Mg, Every 2 Weeks) (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINBLASTINE ^ROGER BELLON^ (10 Mg, Every 2 Weeks) (View Vinblastine ^roger Bellon^ Review and Vinblastine ^roger Bellon^ Label ), DETICENE (720 Mg, Every 2 Weeks) (View Deticene Review and Deticene Label ), DEXAMETHASONE (20 Mg, Every 2 Weeks) (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized and became disabled.

6296263-0 | Heart Disease Congenital
on Jul 23, 2009 Female patient from FRANCE , 59 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Adriblastine (View Usage). Patient experienced the following unwanted or unexpected effects: heart disease congenital. Adriblastine dosage: Unk. During the same period patient was treated with VELCADE (3.5 Mg) (View Velcade Review and Velcade Label ), ONCOVIN (1 Mg) (View Oncovin Review and Oncovin Label ), DECTANCYL (0.5 %) (View Dectancyl Review and Dectancyl Label ), REVLIMID (15 Mg) (View Revlimid Review and Revlimid Label ). Patient was hospitalized and became disabled.

5885338-3 | Haemolytic Anaemia, Methaemoglobinaemia
Patient was taking Adriblastine (View Usage). Patient had the following side effects: haemolytic anaemia, methaemoglobinaemia on Sep 04, 2008 from FRANCE Additional patient health information: Male patient , weighting 176.4 lb, . Adriblastine dosage: . During the same period patient was treated with FASTURTEC (View Fasturtec Review and Fasturtec Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), KYTRIL (View Kytril Review and Kytril Label ), METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

5451722-5 | Agranulocytosis, Aplasia
Adverse event was reported on Sep 03, 2007 by a Male patient taking Adriblastine (View Usage) (Dosage: ) was diagnosed with lymphoma (What is lymphoma?) and. Location: FRANCE , 76 years of age, After Adriblastine was administered, patient had the following side effects: agranulocytosis, aplasia. During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ARANESP (View Aranesp Review and Aranesp Label ), PROPRANOLOL HYDROCHLORIDE (View Propranolol Hydrochloride Review and Propranolol Hydrochloride Label ), NEXIUM (View Nexium Review and Nexium Label ). Patient was hospitalized.

5293878-3 | Blood Calcium Decreased, Dialysis, Febrile Bone Marrow Aplasia, Hypokalaemia, Renal Failure, Tubulointerstitial Nephritis
on Mar 30, 2007 Female patient from FRANCE , 46 years of age, weighting 114.6 lb, was diagnosed with neoplasm malignant and was treated with Adriblastine (View Usage). Patient experienced the following unwanted or unexpected effects: blood calcium decreased, dialysis (What is dialysis?), febrile bone marrow aplasia, hypokalaemia, renal failure, tubulointerstitial nephritis. Adriblastine dosage: . During the same period patient was treated with DETICENE (View Deticene Review and Deticene Label ), HOLOXAN (View Holoxan Review and Holoxan Label ). Patient was hospitalized.

5287155-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Gamma-glutamyltransferase Increased
on Mar 23, 2007 Female patient from FRANCE , 31 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Adriblastine (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased. Adriblastine dosage: Daily Dose:64mg. During the same period patient was treated with ENDOXAN (Daily Dose:940mg) (View Endoxan Review and Endoxan Label ), ONCOVIN (Daily Dose:1.8mg) (View Oncovin Review and Oncovin Label ), MABTHERA (Daily Dose:500mg) (View Mabthera Review and Mabthera Label ), DEXAMETHASONE (Daily Dose:20mg) (View Dexamethasone Review and Dexamethasone Label ), DAFALGAN (Daily Dose:3gram) (View Dafalgan Review and Dafalgan Label ), EFFERALGAN CODEINE (Text:2 To 4 Tablets) (View Efferalgan Codeine Review and Efferalgan Codeine Label ). Patient was hospitalized.

5269360-6 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Gamma-glutamyltransferase Increased
Patient was taking Adriblastine (View Usage). After Adriblastine was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased on Mar 07, 2007 from FRANCE Additional patient health information: Female patient , 31 years of age, was diagnosed with non-hodgkin's lymphoma and. Adriblastine dosage: Daily Dose:64mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (Daily Dose:940mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (Daily Dose:1.8mg) (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (Daily Dose:20mg) (View Dexamethasone Review and Dexamethasone Label ), RITUXIMAB (Daily Dose:500mg) (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

5253509-5 | Renal Failure
Adverse event was reported on Feb 20, 2007 by a Female patient taking Adriblastine (View Usage) (Dosage: ) was diagnosed with neoplasm malignant and. Location: FRANCE , 46 years of age, weighting 114.6 lb, Patient experienced the following unwanted or unexpected effects: renal failure. During the same period patient was treated with DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.